Relapsing Multiple Sclerosis News Today

(RTTNews) - Shares of Merck KgaA (MKGAY.PK) were losing more than 14 percent in the early morning trading in Germany after the science and technol...

(RTTNews) - The major U.S. index futures are currently pointing to a higher open on Wednesday, with stocks likely to move to the upside following ...

European stocks closed higher on Wednesday amid rising optimism several central banks, including the Federal Reserve will consider easing their monetary policy, and even start cutting interest rates sometime early next year.

European stocks closed higher on Wednesday amid rising optimism several central banks, including the Federal Reserve will consider easing their monetary policy, and even start cutting interest rates sometime early next year.

Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th...

Jamie-Lynn Sigler was diagnosed with multiple sclerosis when she was 20-years-old and has welcomed two sons since

Frexalimab, a second-generation CD40L blocker, safely reduced the number of new active brain lesions in relapsing MS patients in a Phase 2 trial.

Patients with multiple sclerosis would accept more relapses per year and a decrease in time to disease progression for fatigue relief.

Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY (diroximel fumarate) consistent with previous

NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I &